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1. Hypertensive myocardial fibrosis
A substantial increase in fibrillar collagen has been
w xobserved in the cardiac ventricles of animals 1 and
w xhumans 2 with arterial hypertension. Either reactive or
reparative hypertensive myocardial fibrosis is the result of
both increased collagen types I and III synthesis by fibrob-
lasts and unchanged or decreased extracellular collagen
w xdegradation 3 . Hemodynamic and non-hemodynamic fac-
tors may be involved in the disequilibrium between colla-
gen synthesis and degradation that occurs in hypertension
w x4 .
w x w xAs shown experimentally 1 and clinically 5,6 , a rise
in collagen content increases myocardial stiffness and pro-
motes abnormalities of cardiac function. In addition, the
perivascular accumulation of collagen fibers may impair
the vasodilator capacity of intramyocardial coronary arter-
ies and contribute to the decrease in coronary reserve,
w xwhich is commonly seen in the hypertensive heart 7 . On
the other hand, alterations in the electrical activity of the
left ventricle in hypertensive patients have been shown to
w xbe related to the degree of myocardial fibrosis 6 .
Although microscopic examination of cardiac biopsies
is the most reliable method for documenting and measur-
ing myocardial fibrosis, the development of non-invasive
methods to indicate the presence of myocardial fibrosis in
hypertensive patients would be useful. We have therefore
applied a biochemical method based on the measurement
of serum peptides derived from the tissue formation and
degradation of fibrillar collagens to monitor the turnover
of these molecules in rats with spontaneous hypertension
 .SHR and in patients with essential hypertension.
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2. Biochemical assessment of fibrillar collagen synthesis
and degradation
2.1. Fibrillar collagen synthesis
Fibrillar collagen is synthesized in the fibroblasts as
procollagen containing an amino-terminal and a carboxy-
 . w xterminal propeptide Fig. 1 8 . After procollagen has been
secreted into the extracellular space, the propeptides are
removed by specific proteinases, allowing integration of
the rigid collagen triple helix into the growing fibril Fig.
. w x1 8 .
The 100-kDa procollagen type I carboxy-terminal
 .propeptide PIP is cleaved from procollagen type I during
the synthesis of fibril-forming collagen type I and is
 .released into the blood-stream Fig. 1 . A stoichiometric
ratio of 1:1 exists between the number of collagen type I
w xmolecules produced and that of PIP released 8 . Circulat-
 . w xing PIP is cleared from the blood by the liver Fig. 1 9 .
Therefore, the serum concentration of PIP has been pro-
posed as a useful marker of collagen type I synthesis in
w xconditions of preserved liver function 10 . This has been
confirmed by several clinical observations demonstrating
that high serum levels of the propeptide measured by
specific radioimmunoassay reflect continuous tissue fibro-
w xsis 11–13 .
The 42-kDa procollagen type III amino-terminal
 .propeptide PIIIP is formed during the conversion of
procollagen type III to collagen type III and is released
 . w xinto the blood in a stoichiometric fashion Fig. 1 8 . As
PIIIP appears to be cleared from the blood via hepatobil-
 . w xiary elimination Fig. 1 14 , the serum levels of this
propeptide have been proposed as a useful marker of
collagen type III synthesis in conditions of preserved bile
w xexcretion 10 . This is sustained by a diversity of clinical
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w x15–17 observations demonstrating that high serum levels
of the propeptide reflect ongoing tissue fibrosis.
2.2. Fibrillar collagen degradation
The rate-limiting step in the degradation of collagen
type I fibrils is catalytic cleavage by interstitial collagenase
 . w xFig. 1 18 . This enzyme cleaves all three alpha chains of
collagen at a single, specific locus located at a distance of
three-fourths from the amino-terminal. The resulting 36-
kDa and 12-kDa telopeptides maintain their helical struc-
ture and are resistant to further proteolytic degradation.
The big telopeptide spontaneously denatures into non-heli-
cal gelatin derivatives which, in turn, are completely de-
 .graded by interstitial gelatinases Fig. 1 .
The small 12-kDa telopeptide resulting from the cleav-
 .age of collagen type I CITP is found in an immunochem-
ically intact form in blood, where it appears to be derived
from tissues with a stoichiometric ratio of 1:1 between the
number of collagen type I molecules degraded and that of
 . w xCITP released Fig. 1 19 . CITP appears to be cleared
 . w xfrom the circulation via glomerular filtration Fig. 1 19 .
w xIn recent studies 19–21 , serum concentrations of the
telopeptide were found to be related to the intensity of the
degradation of collagen type I fibrils in patients with
normal renal function.
3. Fibrillar collagen synthesis and degradation-derived
peptides in arterial hypertension
3.1. Animal studies
w xIn a recent study 22 , we measured serum PIP and
CITP concentrations by specific radioimmunoassays in
 .normotensive Wistar-Kyoto rats WKY , SHR and SHR
 .treated with the angiotensin converting enzyme ACE
inhibitor, quinapril, for 20 weeks. The Masson trichrome
stain was used to evaluate the presence and intensity of
interstitial and perivascular fibrosis of the left ventricle,
and the deposition of collagen type I was assessed by
immunohistochemistry using a specific monoclonal anti-
body.
In untreated SHR, compared with WKY, we found
more extensive interstitial and perivascular fibrosis, in-
creased collagen volume fractions, more marked accumula-
tion of collagen type I, increased serum PIP concentrations
 . w xand similar serum CITP concentrations Table 1 22 . In
quinapril-treated SHR, compared with untreated SHR, we
found marked decreases of fibrosis, lower collagen volume
fractions, diminished accumulation of collagen type I,
decreased PIP concentrations and similar CITP concentra-
 . w xtions Table 1 22 . A direct correlation was found be-
tween the collagen volume fraction and serum PIP in
Fig. 1. Diagrammatic depiction of the different compartments of fibrillar collagen turnover. The origin and destination of the serum markers of collagen
 .  .  .type I synthesis PIP , collagen type III synthesis PIIIP and collagen type I degradation CITP are indicated. 1 s procollagen-specific amino- and
carboxy-terminal proteinases; 2 s collagenase.
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Table 1
Serum markers of fibrillar collagen turnover in arterial hypertension
 .  .  .Experimental condition PIP mgrl CITP mgrl PIPrCITP PIIP ngrml
Rats
 .Normotensive Wistar-Kyoto WKY 8.56"0.56 5.24"0.17 1.60"0.27 y
) ) ) .Spontaneously hypertensive SHR 13.13"0.94 5.86"0.19 2.20"0.39 y
 .Quinapril-treated SHR Q-SHR 8.88"0.62 5.79"0.19 1.53"0.22 y
Humans
 .Normotensive individuals NI 108"6 y y 8.47"0.77
) ) ) ) ) ) .Essential hypertensive EH 139"6 y y 10.08"0.39
 .Lisinopril-treated EH L-EH 111"5 y y 8.42"0.56
w xAdapted from Refs. 22–24 . Values are expressed as mean"s.e.m. PIP s procollagen type I carboxy-terminal propeptide; CITP s collagen type I
carboxy-terminal telopeptide; PIIP s procollagen type III amino-terminal propeptide.
) P -0.01 compared to WKY and Q-SHR; ) ) P -0.05 compared to WKY and Q-SHR; ) ) ) P -0.001 compared to NI and L-EH.
w xuntreated SHR 22 . The ratio between PIP and CITP was
abnormally increased in untreated SHR and became nor-
 .malized after treatment in quinapril-treated SHR Table 1
w x22 .
3.2. Human studies
w x w xWe recently measured serum PIP 23 and PIIIP 23,24
concentrations by specific radioimmunoassays in patients
with essential hypertension who had never been treated
and in normotensive individuals who acted as controls.
Patients with conditions associated with elevated serum
PIP or PIIIP concentrations were excluded. Measurements
were repeated in hypertensive patients after treatment with
the ACE inhibitor lisinopril for 6 months.
w x w xBaseline serum PIP 23 and PIIIP 23,24 concentra-
tions were increased in hypertensive patients, compared
 .with normotensive individuals Table 1 . Serum PIP con-
centrations correlated directly with the left ventricular
w xmass index in the hypertensive group 23 . In addition,
serum PIP concentrations related directly to the Lown-Wolf
grade of ventricular arrhythmias in the hypertensive group
w x23 . On the other hand, serum PIIIP concentrations corre-
lated inversely with maximal early transmitral flow veloc-
w xity measured during diastole 24 and with the ratio be-
tween maximal early transmitral flow velocity and maxi-
mal late transmitral flow velocity measured during diastole
w x23 in the hypertensive group.
Patients treated with lisinopril had normalization in
blood pressure, regression of left ventricular mass index,
amelioration of diastolic filling and a diminution in the
w xnumber of ventricular extrasystoles 23,24 . Serum PIP and
PIIIP concentrations decreased to normal values in these
 . w xpatients Table 1 23,24 .
4. Discussion
w xThe findings of the above studies 22–24 show an
increase in serum concentrations of PIP and PIIIP in
essential hypertensive patients and in SHR. The relations
observed between serum PIP and PIIIP and parameters of
myocardial mass and composition, function and electrical
activity of the left ventricle suggest that these circulating
procollagen-derived propeptides may reflect continuing
myocardial accumulation of fibrillar collagen molecules in
arterial hypertension.
On the other hand, if an equilibrium is to exist between
collagen synthesis and degradation, as proposed by Lau-
w xrent 25 our findings of normal serum concentrations of
w xCITP and increased PIPrCITP ratio in SHR 22 suggest
that the intensity of the extracellular degradation of colla-
gen type I is not enough to equilibrate the increased
extracellular synthesis of collagen type I in this model of
genetic hypertension.
w xInterestingly, we have calculated that in the SHR 22,26
changes in the cardiac compartment of collagen type I can
alter concentrations of PIP and CITP in the circulation and
that other extracardiac sources able to elevate the serum
concentrations of PIP and CITP can be excluded. We
therefore propose that measurement of serum PIP and
CITP concentrations may provide indirect diagnostic infor-
mation on the development of myocardial fibrosis in arte-
rial hypertension.
Due to their pharmacological properties neither quinapril
w x w x27 nor lisinopril 28 seems to stimulate either the hepatic
or the renal elimination of the above three peptides. Ac-
cordingly, the effects of ACE inhibitors on serum PIP and
PIIIP concentrations and the ratio PIPrCITP suggest that
these agents influence the synthesis andror the degrada-
tion of fibrillar collagen. ACE inhibitors can inhibit the
synthesis of fibrillar collagen via suppression of the direct
stimulatory action exerted on fibroblasts by mechanical
w xstrain, angiotensin II and aldosterone 29 . On the other
hand, it has been shown that active collagenase is selec-
tively inhibited by the plasminogen activator inhibitors
 . w xPAIs 30 . Since angiotensin II has the capacity to induce
w xPAIs 31 , it can be proposed that ACE inhibition may
stimulate collagen degradation via the suppression of an-
giotensin-II-dependent PAI synthesis.
5. Conclusions and perspectives
The preliminary experimental and clinical data re-
viewed here suggest that the biochemical monitoring of
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fibrillar collagen turnover may provide a potential non-in-
vasive method of assessing both the presence and mecha-
nisms of myocardial fibrosis and the ability for cardiac
repair of antihypertensive drugs in hypertensive patients.
It is clear that none of the collagen tissue peptides
detectable in serum is exclusively heart-specific or unam-
biguously reflects either fibrogenesis, fibrolysis or fibrosis
in hypertensive heart disease. However, if the diagnosis is
not established, which is still based primarily on histologi-
cal assessment, measurement of these peptides or a combi-
nation of them should provide information not available by
any other known parameter. Nevertheless, we are aware
that further clinical and experimental studies are necessary
to definitively validate this approach.
While a cardiac-based biopsy protocol is not manage-
able and beyond that may be subject to sampling error,
serum tests can be performed on a frequent basis. This
kind of patient control will definitely be necessary, once
the availability of potent antifibrotic drugs triggers clinical
trials or even leads to novel standard treatment for fibro-
genic cardiac diseases, a development which can be antici-
pated in the immediate future.
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